CTSO
Cytosorbents CorporationNASDAQHealthcare$0.58+1.20%ClosedMarket Cap: $36.6M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
6.28
P/S
1.00
EV/EBITDA
-4.49
DCF Value
$-5.34
FCF Yield
-33.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
71.5%
Operating Margin
-38.9%
Net Margin
-22.1%
ROE
-79.9%
ROA
-18.6%
ROIC
-39.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $9.2M | 73.7% | $-4.1M | $-5.5M | $-0.09 | — |
| FY 2025 | $37.1M | 71.5% | $-14.2M | $-8.2M | $-0.13 | — |
| Q3 2025 | $9.5M | 70.3% | $-2.9M | $-3.2M | $-0.05 | — |
| Q2 2025 | $9.6M | 70.9% | $-3.6M | $1.9M | $0.03 | — |
| Q1 2025 | $8.7M | 71.1% | $-3.9M | $-1.5M | $-0.02 | — |
| Q4 2024 | $9.2M | 102.7% | $-4.0M | $-7.9M | $-0.14 | — |
| FY 2024 | $35.6M | 70.6% | $-16.8M | $-20.7M | $-0.38 | — |
| Q3 2024 | $8.6M | 52.3% | $-4.4M | $-2.3M | $-0.04 | — |
| Q2 2024 | $8.8M | 73.5% | $-3.6M | $-4.3M | $-0.08 | — |
| Q1 2024 | $9.0M | 76.5% | $-4.7M | $-6.1M | $-0.11 | — |
| Q4 2023 | $7.3M | 68.1% | $-9.6M | $-6.1M | $-0.13 | — |
| FY 2023 | $31.1M | 70.6% | $-31.9M | $-29.2M | $-0.65 | — |